Drug Pipeline

FT819 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
1
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT06308978
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease		 Trial sites expanded: 18 -> 21 locations
Active Studies by Phase
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07570862 A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis Lupus Nephritis Not Yet Recruiting
Phase 1
NCT06308978 A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) Recruiting
NCT04629729 FT819 in Subjects With B-cell Malignancies Lymphoma, B-Cell Active, Not Recruiting
Sponsors Running FT819 Trials
Fate Therapeutics (3)
Disease Areas
Lupus (SLE) (2) Leukemia (1) Acute Lymphoblastic Leukemia (ALL) (1) Chronic Lymphocytic Leukemia (CLL) (1) Scleroderma (1)
Get alerts when FT819 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free